At a CAGR of 8.1% Pancreatic Cancer Therapy Market Size Worth 2011.2 million | Opportunity, and Analysis in 2025

Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.

The pancreatic cancer therapy market is expected to reach US$ 4056.4 million by 2025 from US$ 2011.2 million in 2017; it is estimated to grow at a CAGR of 8.1% from 2018 to 2025.

Request Exclusive Sample PDF of this Report @

https://www.theinsightpartners.com/sample/TIPMD00002009/

The major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The drug is into phase III of the clinical trials. The developments performed by the companies are helping the market to grow in the coming years.

Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.

The market for pancreatic cancer therapy is expected to grow due to rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs, and increase in number of therapies launched in the market are boosting the market over the years. In addition, development of efficient therapy for pancreatic cancer treatment are likely to have a positive impact on the growth of the pancreatic cancer therapy market in the coming years.

According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.

Interested in Purchasing this Report? Click here @

https://www.theinsightpartners.com/buy/TIPMD00002009/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com